Literature DB >> 15767799

Little or no residual prostate cancer at radical prostatectomy: vanishing cancer or switched specimen?: a microsatellite analysis of specimen identity.

Dengfeng Cao1, Mike Hafez, Karin Berg, Kathleen Murphy, Jonathan I Epstein.   

Abstract

With more vigilant screening for prostate cancer, there has been an associated increase in patients with little or no residual cancer at radical prostatectomy after an initial diagnosis of minute cancer on needle biopsy. This raises a critical question as to whether the biopsy and subsequent radical prostatectomy in these patients are from the same patient. We used PCR-based microsatellite marker analysis to perform identity test in 46 men (35 with minute cancer and 11 with no residual cancer). Of them, 41 were interpretable, including 31 with minute cancer and 10 with no residual cancer. All 31 interpretable cases with minute cancer showed match between the initial biopsy and radical prostatectomy specimens. Nine of the 10 interpretable cases with no residual cancer showed match and 1 showed mismatch. The remaining 5 cases (4 with minute cancer and 1 with no residual cancer) were considered uninterpretable due to technical problems. The initial biopsy of the mismatched case had high-grade cancer (Gleason score 4 + 4 = 8) measuring 9.6 mm in length with perineural invasion. Our results confirm that, in most cases of "vanishing cancer" in radical prostatectomy specimens, it reflects a chance sampling of a minute cancer and not a switch in specimens. However, specimen switch can rarely occur, and if there is high grade or a lot of cancer on the biopsy with no or very minimal cancer in the radical prostatectomy specimen, one should evaluate for patient identity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767799     DOI: 10.1097/01.pas.0000155150.83541.f2

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

1.  Vanishing prostate cancer on radical prostatectomy (RP) in the PSA era: incidence and follow-up data from a cohort of 1,060 patients between 1998 and 2010.

Authors:  Vikas Mehta; Swati Mehrotra; Robert C Flanigan; Eva M Wojcik; Girish Venkataraman
Journal:  Virchows Arch       Date:  2011-05-17       Impact factor: 4.064

2.  Biopsy misidentification identified by DNA profiling in a large multicenter trial.

Authors:  Michael Marberger; John D McConnell; Ivy Fowler; Gerald L Andriole; David G Bostwick; Matthew C Somerville; Roger S Rittmaster
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

Review 3.  DNA comparison between operative and biopsy specimens to investigate stage pT0 after radical prostatectomy.

Authors:  Thomas Bessede; Emmanuelle Girodon; Yves Allory; Annick Le Floch; Karen Leroy; Laurent Salomon
Journal:  World J Urol       Date:  2014-03-27       Impact factor: 4.226

4.  Clinical outcomes of no residual disease in the specimen after endoscopic resection for gastric neoplasms.

Authors:  Ji Min Choi; Sang Gyun Kim; Hyo-Joon Yang; Joo Hyun Lim; Jeongmin Choi; Jong Pil Im; Joo Sung Kim; Woo Ho Kim; Hyun Chae Jung
Journal:  Surg Endosc       Date:  2015-06-20       Impact factor: 4.584

5.  Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy.

Authors:  Roberta Mazzucchelli; Francesca Barbisan; Adriano Tagliabracci; Antonio Lopez-Beltran; Liang Cheng; Marina Scarpelli; Rodolfo Montironi
Journal:  Virchows Arch       Date:  2007-02-07       Impact factor: 4.064

6.  The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer.

Authors:  Jae Young Joung; Jeong Eun Kim; Sung Han Kim; Ho Kyung Seo; Jinsoo Chung; Weon Seo Park; Eun Kyung Hong; Kang Hyun Lee
Journal:  BMC Urol       Date:  2015-08-13       Impact factor: 2.264

Review 7.  Nondetectable Prostate Carcinoma (pT0) after Radical Prostatectomy: A Narrative Review.

Authors:  Nikolaos Kalampokis; Nikolaos Grivas; Markos Karavitakis; Ioannis Leotsakos; Ioannis Katafigiotis; Marcio Covas Moschovas; Henk van der Poel
Journal:  Curr Oncol       Date:  2022-02-23       Impact factor: 3.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.